Back to Careers

One of In Vivo’s 2024 Rising Leaders, Dr. Hanadie Yousef, CEO of Juvena Therapeutics, talks about the secretome as a source of therapeutics, the company’s lead assets, the future of longevity medicine and learning as you go as a biotech entrepreneur.

Back to Careers

Juvena’s CMO Dr. Barney King participates in the Myotonic Dystrophy Regional Summit, where Juvena gave an industry presentation.

Back to Careers

CEO Dr. Hanadie Yousef participates in a panel on “Demystifying Aging” at Horizons Ventures 2024 Techcracker summit 

Back to Careers

Juvena CEO and CO-Founder Dr. Hanadie Yousef featured in San Francisco Business Times article highlighting women biotech leaders

Back to Careers

Ashil Koranne presented a poster at the 2024 MDA Clinical & Scientific Conference highlighting Juvena Therapeutics’ promising preclinical development of JUV-161, a novel fusion protein for treating Myotonic Dystrophy Type 1.

Back to Careers

Juvena recognized by The Wall Street Journal for developing regenerative therapies aimed at weight loss and prevention of muscle wasting

Back to Careers

Juvena gets FDA Orphan Drug nod for muscle regeneration therapy

Back to Careers

Juvena’s JUV-161 awarded US orphan drug designation for myotonic dystrophy type 1

juvena-logo-wht

Navigation

Contact

640 Galveston Drive
Redwood City, CA 94063
Get Directions »
650.223.5879
info@juvenatherapeutics.com

Stay in touch

Subscribe to our newsletter

By entering your email you agree to our Privacy Policy

© 2023 Juvena Therapeutics Inc. All Rights Reserved | Privacy Policy